Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
- Written by PR Newswire Asia - News Pronto RSS
--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU--
SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s partner Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing...